Susquehanna International Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-757
Closed -$171K 14068
2022
Q3
$171K Buy
+757
New +$186K ﹤0.01% 11069
2022
Q2
Sell
-1,307
Closed -$325K 14245
2022
Q1
$325K Sell
1,307
-290
-18% -$45.8K ﹤0.01% 10084
2021
Q4
$249K Sell
1,597
-80
-5% -$15.5K ﹤0.01% 10956
2021
Q3
$336K Buy
1,677
+110
+7% +$26.2K ﹤0.01% 10334
2021
Q2
$400K Sell
1,567
-1,843
-54% -$460K ﹤0.01% 10136
2021
Q1
$905K Sell
3,410
-1,600
-32% -$504K ﹤0.01% 7997
2020
Q4
$1.85M Sell
5,010
-2,197
-30% -$630K ﹤0.01% 5261
2020
Q3
$1.76M Buy
+7,207
New +$2.24M ﹤0.01% 4877
2020
Q2
Sell
-380
Closed -$78K 11148
2020
Q1
$78K Sell
380
-27
-7% -$8.61K ﹤0.01% 9471
2019
Q4
$182K Buy
+407
New +$144K ﹤0.01% 8832
2015
Q4
Sell
-96
Closed -$46K 10106
2015
Q3
$46K Sell
96
-332
-78% -$176K ﹤0.01% 9384
2015
Q2
$243K Sell
428
-224
-34% -$620K ﹤0.01% 8943
2015
Q1
$5.55M Buy
+652
New +$5.7M ﹤0.01% 2591

Other funds holding EIGR

Susquehanna International Group's EIGR Position: Q1 2024 in Review

Susquehanna International Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 850 shares — an estimated $5.73K sold.

Susquehanna International Group first reported a position in EIGR in Q4 2014 and held it in 22 quarters. The position peaked at $1.27M in Q1 2019. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Susquehanna International Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Susquehanna International Group sold 850 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $5.73K.
  • Susquehanna International Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 22 quarters.
  • Susquehanna International Group's Eiger BioPharmaceuticals, Inc. position peaked at $1.27M in Q1 2019.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.